Epstein Barr Virus (EBV) is a ubiquitous human lymphotropic herpesvirus which is also called Gamma herpesvirus and has been involved in several cancers. EBV is the first human tumor virus identified. There has been much epidemiological and mechanistic evidence to prove the causal role of EBV in multiple sclerosis (MS). Multiple Sclerosis is a chronic autoimmune disease of the central nervous system characterized by demyelination and neuroinflammation. For this paper, I aim to provide answers to questions like how a virus, which leads to benign latent infection, can promote cancers and autoimmune disease, how EBV plays an important role in the development of multiple sclerosis, how EBV is involved in the pathogenesis of multiple sclerosis and how this study will help to find the way for future MS treatments. Scientists have long suspected but failed to prove the link between viruses and multiple sclerosis (autoimmune disease). A study led by Stanford Medicine researchers proves that EBV triggers multiple sclerosis by priming the immune system to attack the body’s nervous system. This research paper aims to provide an overview of the current understanding of the role of Epstein Barr Virus in the pathogenesis of multiple sclerosis.
Cite this paper
Pandey, B. (2024). The Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis. Open Access Library Journal, 11, e2227. doi: http://dx.doi.org/10.4236/oalib.1112227.
Begum, J. and Wat-son, S. (2023) Epstein Barr Virus Infection: Symptoms, Diagnosis and Treat-ment. https://www.webmd.com/a-to-z-guides/epstein-barr-virus
IARC (1997) IARC Monographs on the Evaluation of Carcinogenic Risks to Humans: Volume 70. Epstein Barr Virus. https://www.ncbi.nlm.nih.gov/books/NBK385500/
Bach, J.-F. (2002) The Effect of Infections on Susceptibility to Autoimmune and Aller-gic Diseases. The New England Journal of Medicine, 347, 911-920. https://www.nejm.org/doi/full/10.1056/NEJMra020100
Munger, K. and Ascherio, A. (2016) Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update. Seminars in Neurology, 36, 103-114. https://doi.org/10.1055/s-0036-1579693
Harley, J.B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., et al. (2018) Transcrip-tion Factors Operate across Disease Loci, with EBNA2 Implicated in Autoim-munity. Nature Genetics, 50, 699-707. https://doi.org/10.1038/s41588-018-0102-3
Afrasiabi, A., et al. (2019) Evidence from Genome Wide Association Studies Implicates Reduced Control of Epstein-Barr Virus Infection in Multiple Sclerosis Susceptibility. Genome Medi-cine, 11, 26.
Virtanen, J.O., Wohler, J., Fenton, K., Reich, D.S. and Ja-cobson, S. (2014) Oligoclonal Bands in Multiple Sclerosis Reactive against Two Herpesviruses and Association with Magnetic Resonance Imaging Findings. Mul-tiple Sclerosis, 20, 27-34.
Lunemann, J.D., Jelcic, I., Roberts, S., Lutterotti, A., Tackenberg, B., Martin, R., et al. (2008) EBNA1-Specific T Cells from Patients with Multiple Sclerosis Cross React with Myelin Antigens and Co-Produce IFN-Gamma and Il-2. The Journal of Experi-mental Medicine, 205, 1763-1773. https://doi.org/10.1084/jem.20072397
Dirmeier, U., Hoffmann, R., Kilger, E., Schultheiss, U., Briseno, C., Gires, O., et al. (2005) Latent Membrane Protein 1 of Epstein-Barr Virus Coordinately Regulates Proliferation with Con-trol of Apoptosis. Oncogene, 24, 1711-1717. https://doi.org/10.1038/sj.onc.1208367
van Langelaar, J., Wierenga-Wolf, A.F., Samijn, J.P.A., Luijks, C.J.M., Siepman, T.A., van Doorn, P.A., et al. (2020) The Association of Epstein-Barr Virus Infection with CXCR3 B-Cell Development in Multiple Sclerosis: Impact of Immunotherapies. Europe-an Journal of Immunology, 51, 626-633. https://doi.org/10.1002/eji.202048739
Zivadinov, R., Guan, Y., Jakimovski, D., Ramanathan, M. and Weinstock-Guttman, B. (2019) The Role of Epstein-Barr Virus in Multiple Sclerosis: From Molecular Pathophysiology to in Vivo Imaging. Neural Regeneration Research, 14, 373-386. https://doi.org/10.4103/1673-5374.245462
Pender, M.P. (2010) The Essential Role of Epstein-Barr Virus in the Pathogenesis of Multiple Sclerosis. The Neuroscientist, 17, 351-367. https://doi.org/10.1177/1073858410381531
Bjornevik, K., Münz, C., Cohen, J.I. and Ascherio, A. (2023) Epstein-Barr Virus as a Leading Cause of Multiple Sclerosis: Mechanisms and Implications. Nature Reviews Neurology, 19, 160-171. https://doi.org/10.1038/s41582-023-00775-5
Giovannoni, G. (2024) Targeting Epstein-Barr Virus in Multiple Sclero-sis: When and How? Current Opinion in Neurology, 37, 228-236. https://doi.org/10.1097/wco.0000000000001266
National Toxicology Program (2016) Report on Carcinogens Monograph on Epstein-Barr Virus: RoC Monograph 07. https://www.ncbi.nlm.nih.gov/books/NBK582491/
Hauser, S.L., et al. (2017) Ocrelizumab versus Interferon Beta-la in Relapsing Multiple Sclero-sis. The New England Journal of Medicine, 376, 221-234. https://pubmed.ncbi.nlm.nih.gov/28002679/
Cencioni, M.T., Magliozzi, R., Nicholas, R., Ali, R., Malik, O., Reynolds, R., et al. (2017) Programmed Death 1 Is Highly Expressed on CD8 CD57 T Cells in Patients with Stable Multiple Sclerosis and Inhibits Their Cytotoxic Response to Epstein-Barr Virus. Immu-nology, 152, 660-676. https://doi.org/10.1111/imm.12808
Jilek, S., Schluep, M., Meylan, P., Vingerhoets, F., Guignard, L., Monney, A., et al. (2008) Strong Ebv-Specific CD8 T-Cell Response in Patients with Early Multiple Sclerosis. Brain, 131, 1712-1721. https://doi.org/10.1093/brain/awn108
Pender, M.P. and Khanna, R. (2014) Epstein-Barr Virus-Specific Adoptive Immunotherapy: A New Horizon for Multiple Sclerosis Treatment? Immunotherapy, 6, 659-661. https://doi.org/10.2217/imt.14.43
van Noort, J.M., Ba-jramovic, J.J., Plomp, A.C. and van Stipdonk, M.J.B. (2000) Mistaken Self, a Nov-el Model That Links Microbial Infections with Myelin-Directed Autoimmunity in Multiple Sclerosis. Journal of Neuroimmunology, 105, 46-57. https://doi.org/10.1016/s0165-5728(00)00181-8
Wucherpfennig, K.W. and Strominger, J.L. (1995) Molecular Mimicry in T Cell-Mediated Autoimmun-ity: Viral Peptides Activate Human T Cell Clones Specific for Myelin Basic Pro-tein. Cell, 80, 695-705. https://doi.org/10.1016/0092-8674(95)90348-8
Li, R., Rezk, A., Healy, L.M., Muirhead, G., Prat, A., Gommerman, J.L., et al. (2016) Cytokine-Defined B Cell Responses as Therapeutic Targets in Multiple Sclerosis. Frontiers in Immu-nology, 6, Article No. 626. https://doi.org/10.3389/fimmu.2015.00626
D’Addario, M., Libermann, T.A., Xu, J., Ahmad, A. and Menezes, J. (2001) Epstein-Barr Virus and Its Gly-coprotein-350 Upregulate IL-6 in Human B-Lymphocytes via CD21, Involving Activation of NF-κB and Different Signaling Pathways. Journal of Molecular Bi-ology, 308, 501-514. https://doi.org/10.1006/jmbi.2001.4589
Michel, L., Touil, H., Pikor, N.B., Gommerman, J.L., Prat, A. and Bar-Or, A. (2015) B Cells in the Multiple Sclerosis Central Nervous System: Trafficking and Contribution to CNS-Compartmentalized Inflammation. Frontiers in Immunology, 6, Article No. 636. https://doi.org/10.3389/fimmu.2015.00636
Hemminki, K., et al. (2009) Risk for Multiple Sclerosis in Relatives and Spouses of Patients Diag-nosed with Autoimmune and Related Conditions. Neurogenetics, 10, 5-11. https://pubmed.ncbi.nlm.nih.gov/18843511/
Zivadinov, Z., et al. (2018) Effect of Teriflunomide on Gray and White Matter Brain Pathology in Multiple Sclerosis Using Volumetric and Diffusion-Tensor Imaging MRI Measures. Journal of the Neurological Sciences, 388, 175-181. https://pubmed.ncbi.nlm.nih.gov/29627017/
Michelli, R., et al. (2015) Epstein Barr Virus Genetic Variants Are Associated with Multiple Sclerosis. Neurology, 84, 1362-1368. https://pubmed.ncbi.nlm.nih.gov/25740864/
Friedman, J.E., et al. (2005) A Randomized Clinical Trial of Valacyclovir in Multiple Sclerosis. Multiple Sclerosis, 11, 286-295. https://pubmed.ncbi.nlm.nih.gov/15957509/
Belshe, R.B., et al. (2012) Efficacy Results of a Trial of a Herpes Simplex Vaccine. The New England Journal of Medicine, 366, 34-43. https://pubmed.ncbi.nlm.nih.gov/22216840/
Cohen, J.I. (2018) Vaccine Development for Epstein Barr Virus. Advances in Experimental Medicine and Biology, 1045, 477-493. https://pubmed.ncbi.nlm.nih.gov/29896681/
Balfour Jr., H.H., et al. (2020) The Promise of a Prophylactic Epstein Barr Virus Vaccine. Pediatric Re-search, 87, 345-352. https://pubmed.ncbi.nlm.nih.gov/31641280/
Comabella, M., et al. (2012) EBV-Specific Immune Responses in Patients with Multiple Sclerosis Re-sponding to IFNB Therapy. Multiple Sclerosis, 18, 605-609. https://pubmed.ncbi.nlm.nih.gov/22020417/
Rizzo, F., Giacomini, E., Mechelli, R., Buscarinu, M.C., Salvetti, M., Severa, M., et al. (2016) Interferon-β Therapy Specifically Reduces Pathogenic Memory B Cells in Multi-ple Sclerosis Patients by Inducing a FAS-Mediated Apoptosis. Immunology & Cell Biology, 94, 886-894. https://doi.org/10.1038/icb.2016.55
